Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 19

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 19
---
 MTA, Shuttle Pharma agreed to transfer research quantities of candidate    
 drug molecules to Georgetown University, which materials will be used by Georgetown University solely to carry out additional research 
 for Shuttle Pharma and which materials shall at all times remain the property of Shuttle Pharma.                                       |

| ● | Brown      
 University |

| ○ | Sub-contractor                                                           
 of the SBIR supported Phase I clinical trial of IPdR and RT (completed). |

| ● | University  
 of Virginia |

| ○ | Research                                                                                      
 collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications. |

| ● | George                
 Washington University |

| ○ | Material                                                                                                                              
 transfer agreement for testing HDAC inhibitor effects in immune model systems.                                                        |
| ○ | The                                                                                                                                   
 material transfer agreement that protects our HDAC inhibitor intellectual property is with George Washington University, transferring 
 drugs for research purposes and sharing authorship on publications. There is no transfer of funds related to such activities.         |

| ● | Propagenix, 
 Inc.        |

| ○ | License                                                                                                                            
 agreement for “conditional re-programmed cell” (CRC) technology. The cells established by Shuttle Pharma scientists at             
 Georgetown University belong to us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid to 
 Propagenix. No other future milestone or royalty payments owed related to the Propagenix agreement.                                |

| 14 |

Competition “Off-Label” Use

Drugs with radiation sensitizing properties.

Our Product Candidates

We are advancing a clinical stage product candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue when used in conjunction with RT.

Ropidoxuridine

Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead “clinical phase” product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the effects of RT. We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine